A single serum test for measuring early pregnancy outcome with high predictive value.

Area of Science:

• Reproductive Endocrinology
• Clinical Chemistry
• Biomarker Discovery

Background:

• Current methods for diagnosing pregnancy failure involve two clinic visits to assess human chorionic gonadotropin (hCG) levels.
• Emergency departments require simplified and accelerated diagnostic tools for early pregnancy failure.
• Hyperglycosylated hCG (hCG-H) is investigated as a potential biomarker for predicting pregnancy outcomes.

Purpose of the Study:

• To evaluate the utility of hyperglycosylated hCG (hCG-H) as a single-test biomarker for predicting early pregnancy failure.
• To compare the diagnostic accuracy of hCG-H with standard hCG testing in both serum and urine samples.

Main Methods:

• Two independent sets of early gestation patient samples (serum and urine) were analyzed.
• Automated chemiluminescence immunoassays were used to measure hCG and hCG-H concentrations.
• Scattergram analysis and comparison of failing versus continuing pregnancies were performed.

Main Results:

• A threshold of 13 microg/L for hCG-H in serum and urine samples effectively identified pregnancies likely to fail.
• hCG-H demonstrated higher detection rates for pregnancy failure (73-75%) compared to hCG (42-43%) at similar false positive rates.
• hCG-H testing showed improved sensitivity in both serum and urine samples.

Conclusions:

• Hyperglycosylated hCG (hCG-H) offers a more accurate single-test prediction of pregnancy outcome than standard hCG testing.
• A single hCG-H test, using either serum or urine, could provide a simpler, faster, and more accurate method for assessing pregnancy progression.
• This biomarker has the potential to streamline early pregnancy failure diagnosis.